Clinical outcomes of 5-day administration of topotecan combined with bevacizumab for platinum-resistant ovarian cancer: a multicenter retrospective analysis
International Journal of Clinical Oncology · 31.10.2026
DOI: 10.1007/s10147-026-03229-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 31.10.2026. Verfasst von Eriko Takatori und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
The combination of topotecan and bevacizumab is a treatment option for platinum-resistant ovarian cancer. However, the efficacy and safety of the standard 5-day topotecan regimen in real-world practice remain unclear. This study evaluated the clinical outcomes of 5-day topotecan plus bevacizumab in a heavily pretreated population.
Methods
This two-institution retrospective analysis included patients with platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancers treated with a 5-day topotecan plus bevacizumab regimen. Progression-free survival (PFS), overall survival (OS), antitumor efficacy, and treatment-related toxicities were assessed. Cox proportional hazards models were used to identify the prognostic factors.
Results
Fifty-four patients were included. The median number of prior chemotherapy regimens was 3, and 85% had previously received bevacizumab. The median PFS and OS were 4.0 and 11.0 months, respectively. No clinical variables were significantly associated with PFS in univariate analysis; however, histological subtype was associated with PFS in the multivariable model. The objective response rate was 18.5%, and the disease control rate was 57.4%. Hematologic toxicities were frequent and severe: grade ≥ 3 neutropenia occurred in 81.5% of patients, and grade ≥ 3 thrombocytopenia occurred in 37.0%. Gastrointestinal perforation occurred in two patients.
Conclusions
The combination of 5-day topotecan and bevacizumab showed limited clinical benefits and substantial hematologic toxicity in heavily pretreated patients with platinum-resistant ovarian cancer. This regimen may not provide an optimal balance between efficacy and tolerability, underscoring the need for prospective studies to identify patients who may benefit from and optimize treatment sequencing in this era of prior bevacizumab and PARP inhibitor exposure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan.
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. tshoji@iwate-med.ac.jp.
- Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, Hachinohe, Japan.
Zitieren
APA
Takatori, E., Shoji, T., Jo, A., Tatsuki, S., Takagi, S., Jonai, N., Chiba, Y., Sato, S., Kaido, Y., Nagasawa, T., Kagabu, M., Aida, T., & Baba, T. (2026). Clinical outcomes of 5-day administration of topotecan combined with bevacizumab for platinum-resistant ovarian cancer: a multicenter retrospective analysis. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03229-2
Vancouver
Takatori E, Shoji T, Jo A, Tatsuki S, Takagi S, Jonai N, et al. Clinical outcomes of 5-day administration of topotecan combined with bevacizumab for platinum-resistant ovarian cancer: a multicenter retrospective analysis. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03229-2
BibTeX
@article{Takatori2026,
author = {Takatori, Eriko and Shoji, Tadahiro and Jo, Ami and Tatsuki, Shunsuke and Takagi, Shun and Jonai, Nanako and Chiba, Yohei and Sato, Sho and Kaido, Yoshitaka and Nagasawa, Takayuki and Kagabu, Masahiro and Aida, Takeshi and Baba, Tsukasa},
title = {Clinical outcomes of 5-day administration of topotecan combined with bevacizumab for platinum-resistant ovarian cancer: a multicenter retrospective analysis},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03229-2}
}
EUVIMED